3 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
Follow Newly Diagnosed: new trials by email Literature Review of Newly Diagnosed trials Research Report on Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, Zanubrutinib, bendamustine, rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 63 | 2022-03-22 | 2022-03-31 |
| Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML Cladribine Injection, Aclarubicin, G-CSF - Acute Myeloid Leukemia, Elderly Patients | Phase 2 | Unknown | Sun Yat-sen University | 34 | 2021-03-01 | 2020-12-17 |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2020-09-25 | 2023-06-18 |
Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Neoplasms, Plasma Cell (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Chronic Disease (1) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Pathologic Processes (1)
Aclarubicin (1) · Bendamustine Hydrochloride (1) · Bortezomib (1) · Cladribine (1) · Cyclophosphamide (1) · Cytarabine (1) · Dexamethasone (1) · Granulocyte Colony-Stimulating Factor (1) · Lenalidomide (1) · Rituximab (1) · dexamethasone acetate (1) · fludarabine (1) · zanubrutinib (1)
Sun Yat-sen University (2) · Institute of Hematology & Blood Diseases Hospital, China (1)
China (3)
Hua Wang, MD. (1) · Shuhua Yi (1)